Tenecteplase Before Transfer for Blocked Basilar Artery Stroke

Trial details

Who runs it

Xuanwu Hospital, Beijing

Trial code

NCT07203625

Record updated

19 March 2026

Original description

This study is designed to investigate the efficacy and safety of intravenous tenecteplase before interhospital transfer from a non-endovascular capable center(nECC) to an endovascular capable center (ECC) for thrombectomy in patients with acute ischemic stroke (AIS) caused by neuroimaging-confirmed acute basilar artery occlusion (BAO) between 4.5-24 hours of symptom onset.Read full original descriptionShow less

Intravenous Tenecteplase Before Interhospital Transfer for Thrombectomy in Acute Basilar Artery Occlusion at 4.5 to 24 Hours

This study is designed to investigate the efficacy and safety of intravenous tenecteplase before interhospital transfer from a non-endovascular capable center(nECC) to an endovascular capable center (ECC) for thrombectomy in patients with acute ischemic stroke (AIS) caused by neuroimaging-confirmed acute basilar artery occlusion (BAO) between 4.5-24 hours of symptom onset.

Inclusion: Age ≥18 years; Patients presenting with posterior circulation ischemic stroke symptoms due to BAO; BAO confirmed by computed tomographic angiography (CTA)/ magnetic resonance angiography (MRA); Time from AIS symptom onset to randomization within 4.5-24 hours, stroke onset is defined as the onset of acute symptoms leading to the clinical diagnosis of basilar artery occlusion (BAO) not considering the time of any preceding minor prodromal symptoms (such as isolated vertigo, diplopia or sensory changes) as onset time or, if not known, the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke); Baseline National Institute of Health Stroke Scale (NIHSS) score obtained prior to randomization ≥6; Functionally independent (modified Rankin Scale [mRS] 0-2) prior to stroke onset; Intended to transfer for thrombectomy. Two paradigms are allowed in this study: (1)transferring patients to ECC (patient transfer); (2)travelling neurointerventionist to nECC (physician transfer); Written informed consent from patients or legally responsible representatives.

Exclusion: Treatment with a thrombolytic within the last 72 hours or intention to receive intravenous thrombolysis; Ischemic stroke or myocardial infarction in previous 3 months; Previous intracranial hemorrhage, active internal bleeding (gastrointestinal or urinary tract hemorrhage) in previous 3 months; Posterior Circulation Acute Stroke Prognosis Early CT score (PC-ASPECTS) < 6 on computed tomography (CT)/CTA-Source Images/MRI with diffusion-weighted imaging (DWI); CT/MR shows evidence of intracranial hemorrhage and tumor (except small meningioma); Simultaneous occlusion of both anterior and posterior circulation confirmed by CTA/MRA/DSA (patients with a history of occlusion of anterior circulation more than three months ago can be included); Known hypersensitivity or allergy to any ingredients of Tenecteplase; Severe, uncontrolled hypertension (systolic blood pressure >185mmHg or diastolic blood pressure >110mmHg); Known severe, life-threatening allergy (more severe than skin rash) to contrast agents; Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery; Other serious, advanced or terminal illness with life expectancy less than 6 months; Any condition that, in the judgement of the investigator, is inappropriate for participation in the trial or could impose hazards to the patient (e.g. inability to understand and/or follow the study procedures and/or follow-up due to mental disorders, cognitive or emotional disorders); Impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, international normalized ratio (INR) >1.7 or prothrombin time >15s; if use of any direct oral anticoagulant within the last 48 hours; if use of heparin/heparinoid within the last 24 hours; Baseline blood glucose <50mg/dl or >400mg/dl; Baseline platelet count <100,000/μL; Undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency with glomerular filtration rate <30mL/min or serum creatinine >220mmol/L (2.5mg/dL); Complete cerebellar infarct on CT/MRI with significant mass effect and compression of the 4th ventricle; Bilateral extensive brainstem infarction on CT/MRI; Any other contra-indication for intravenous thrombolysis except for the time criteria; Known hereditary or acquired hemorrhagic diathesis; Known diagnosis or clinical suspicion of cerebral vasculitis; Known diagnosis or clinical suspicion of endocarditis; Pregnancy or lactating; Current participation in any investigational study that may confound outcome assessment of the study.

ClinicalTrials.gov NCT07203625